Literature DB >> 20494694

The importance of identifying and validating prognostic factors in oncology.

Susan Halabi1, Kouros Owzar.   

Abstract

Prognosis plays a vital role in patient management and decision making. The assessment of prognostic factors, which relate baseline clinical and experimental covariables to outcomes, is one of the major objectives in clinical research. Historically, the impetus for the identification of prognostic factors has been the need to accurately estimate the effect of treatment adjusting for these variables. In oncology, the variability in outcome may be related to prognostic factors rather than to differences in treatments. In this article, we begin with a brief review of prognostic factors, and then subsequently offer a general discussion of their importance. Next, we describe the significance of study design before presenting various modeling approaches for identifying these factors and discussing the relative values of the different approaches. We illustrate the concepts within the framework of published and ongoing phase III trials in oncology. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20494694      PMCID: PMC2929829          DOI: 10.1053/j.seminoncol.2010.04.001

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  22 in total

1.  Sample size considerations for the evaluation of prognostic factors in survival analysis.

Authors:  C Schmoor; W Sauerbrei; M Schumacher
Journal:  Stat Med       Date:  2000-02-29       Impact factor: 2.373

2.  Internal validation of predictive models: efficiency of some procedures for logistic regression analysis.

Authors:  E W Steyerberg; F E Harrell; G J Borsboom; M J Eijkemans; Y Vergouwe; J D Habbema
Journal:  J Clin Epidemiol       Date:  2001-08       Impact factor: 6.437

3.  Predictive factors of response to first-line chemotherapy in 1426 women with metastatic breast cancer.

Authors:  M Robain; J Y Pierga; M Jouve; B Asselain; V Diéras; P Beuzeboc; T Palangié; T Dorval; J M Extra; S Scholl; P Pouillart
Journal:  Eur J Cancer       Date:  2000-12       Impact factor: 9.162

4.  A new approach to modelling interactions between treatment and continuous covariates in clinical trials by using fractional polynomials.

Authors:  Patrick Royston; Willi Sauerbrei
Journal:  Stat Med       Date:  2004-08-30       Impact factor: 2.373

5.  Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480.

Authors:  D J George; S Halabi; T F Shepard; N J Vogelzang; D F Hayes; E J Small; P W Kantoff
Journal:  Clin Cancer Res       Date:  2001-07       Impact factor: 12.531

6.  Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

Authors:  Susan Halabi; Eric J Small; Philip W Kantoff; Michael W Kattan; Ellen B Kaplan; Nancy A Dawson; Ellis G Levine; Brent A Blumenstein; Nicholas J Vogelzang
Journal:  J Clin Oncol       Date:  2003-04-01       Impact factor: 44.544

7.  What do we mean by validating a prognostic model?

Authors:  D G Altman; P Royston
Journal:  Stat Med       Date:  2000-02-29       Impact factor: 2.373

8.  Tree-based model for breast cancer prognostication.

Authors:  Mousumi Banerjee; Julie George; Eun Young Song; Anuradha Roy; William Hryniuk
Journal:  J Clin Oncol       Date:  2004-07-01       Impact factor: 44.544

9.  Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration.

Authors:  Oren Smaletz; Howard I Scher; Eric J Small; David A Verbel; Alex McMillan; Kevin Regan; W Kevin Kelly; Michael W Kattan
Journal:  J Clin Oncol       Date:  2002-10-01       Impact factor: 44.544

10.  Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease.

Authors:  James A Eastham; William K Kelly; Gary D Grossfeld; Eric J Small
Journal:  Urology       Date:  2003-12-29       Impact factor: 2.649

View more
  22 in total

1.  Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy.

Authors:  Andrea B Apolo; Irina Ostrovnaya; Susan Halabi; Alexia Iasonos; George K Philips; Jonathan E Rosenberg; Jamie Riches; Eric J Small; Matthew I Milowsky; Dean F Bajorin
Journal:  J Natl Cancer Inst       Date:  2013-02-14       Impact factor: 13.506

2.  Why many oncologists fail to share accurate prognoses: They care deeply for their patients.

Authors:  Eli Rowe Abernethy; Gavin Paul Campbell; Rebecca D Pentz
Journal:  Cancer       Date:  2019-11-27       Impact factor: 6.860

3.  The survival impact of palliative chemotherapy dose modifications on metastatic colon cancer.

Authors:  Mohd Naqib Zainal Abidin; Marhanis Salihah Omar; Farida Islahudin; Noraida Mohamed Shah
Journal:  BMC Cancer       Date:  2022-07-04       Impact factor: 4.638

4.  Prognostic factors for patients with anal cancer treated with conformal radiotherapy-a systematic review.

Authors:  Alexandra Gilbert; Ane L Appelt; Stelios Theophanous; Robert Samuel; John Lilley; Ann Henry; David Sebag-Montefiore
Journal:  BMC Cancer       Date:  2022-06-03       Impact factor: 4.638

5.  Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy.

Authors:  Susan Halabi; Chen-Yen Lin; Eric J Small; Andrew J Armstrong; Ellen B Kaplan; Daniel Petrylak; Cora N Sternberg; Liji Shen; Stephane Oudard; Johann de Bono; Oliver Sartor
Journal:  J Natl Cancer Inst       Date:  2013-10-17       Impact factor: 13.506

6.  On model specification and selection of the Cox proportional hazards model.

Authors:  Chen-Yen Lin; Susan Halabi
Journal:  Stat Med       Date:  2013-06-19       Impact factor: 2.373

7.  A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel.

Authors:  K N Chi; T Kheoh; C J Ryan; A Molina; J Bellmunt; N J Vogelzang; D E Rathkopf; K Fizazi; P W Kantoff; J Li; A A Azad; B J Eigl; D Y C Heng; A M Joshua; J S de Bono; H I Scher
Journal:  Ann Oncol       Date:  2015-12-18       Impact factor: 32.976

8.  Predictability of early changes in derived neutrophil-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors.

Authors:  Jeong Uk Lim; Hye Seon Kang; Chang Dong Yeo; Ju Sang Kim; Chan Kwon Park; Jin Woo Kim; Seung Joon Kim; Sang Haak Lee
Journal:  J Thorac Dis       Date:  2021-05       Impact factor: 2.895

Review 9.  Special considerations in prognostic research in cancer involving genetic polymorphisms.

Authors:  Sevtap Savas; Geoffrey Liu; Wei Xu
Journal:  BMC Med       Date:  2013-06-17       Impact factor: 8.775

10.  Identification of novel prognosis-related genes associated with cancer using integrative network analysis.

Authors:  YongKiat Wee; Yining Liu; Jiachun Lu; Xiaoyan Li; Min Zhao
Journal:  Sci Rep       Date:  2018-02-19       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.